BioSpace News Archive

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the 2022 Alzheimer’s Association International Conference (AAIC).

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared Armata’s Investigational New Drug (IND) application for AP-SA02 in prosthetic joint infection (PJI).

Biosight Ltd., announced today that the United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to aspacytarabine (BST-236), an investigational novel antimetabolite, for the treatment of myelodysplastic syndromes, in addition to the Orphan Drug Designation granted in 2019 for aspacytarabine for the treatment of acute myeloid leukemia (AML).

Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced the formation of a Scientific Advisory Board (SAB).

Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB), a new connected and automated microscope designed to advance the pace of cryo-electron tomography (cryo-ET) research.

ENDRA Life Sciences to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 15, 2022, to provide a business update and review the company’s financial results for the quarter ended June 30, 2022.

CorMedix Inc. today announced that it will report its financial results for the second quarter ended June 30, 2022, before the market open on Thursday, August 11, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has completed the pre-specified blinded interim sample size analysis in the COVAMID trial to evaluate its Bentrio nasal spray in patients with acute COVID-19.